# Advisor Review - GPT-5.2

**Role:** Academic advisor checking for fatal errors
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-03-03T19:29:35.301462
**Route:** OpenRouter + LaTeX
**Paper Hash:** 6d87dd166cb74811
**Tokens:** 21829 in / 1430 out
**Response SHA256:** 27e63850ac970d8e

---

## 1) Data–Design Alignment (CRITICAL)

- **Treatment timing vs data coverage:** The treatment is the 14:00 ET cutoff, which exists throughout the stated sample period. The paper’s arXiv submission window is **2012–2024**, and outcomes are measured through **early 2026**. No cohort appears to require treatment or outcomes outside the stated coverage.
- **Post-treatment observations / support around cutoff:** This is an RDD; tables report **effective N on both sides** (e.g., Table `tab:adoption` shows 56/30 left/right), so there is data on both sides of the cutoff within the chosen bandwidths.
- **Treatment definition consistency:** “After cutoff” is consistently defined as submission after 14:00 ET, and that is what is used throughout the RDD and Cox tables. No conflicting “first treated year” type definitions appear (not a staggered adoption design).

No fatal data-design misalignment found.

## 2) Regression Sanity (CRITICAL)

I scanned all reported result tables for broken outputs (implausible coefficients/SEs, impossible statistics, NA/Inf):

- **Table `tab:adoption` (Primary RDD):** Coefficients are small (≈ -0.02), SEs ≈ 0.04–0.05. Nothing mechanically implausible.
- **Table `tab:cox` (Cox within bandwidth):** Coefs -0.247 (SE 0.318) and -0.189 (SE 0.224); hazard ratios consistent with exp(coef). No impossibilities.
- **Table `tab:citations` (log outcomes):** Coefs around -0.6 to -1.1 with SE 0.5–0.9. For log(cites+1), these magnitudes are plausible and not in the “obviously broken” range.
- **Table `tab:robustness`, `tab:placebo`, `tab:polykernel`, `tab:balance`, `tab:heterogeneity`, `tab:dow`:** No NA/NaN/Inf. SEs not absurdly large. No negative SEs or R² issues (R² not reported, which is fine).

No fatal regression sanity issues found.

## 3) Completeness (CRITICAL)

- No placeholders like **TBD / TODO / NA** in the main results tables.
- Regression-style tables report uncertainty (SEs) and report sample size information via **Eff. N** (RDD) and **Observations/Events** (Cox). This meets the “must report N” requirement in spirit for these estimators.
- All in-text references to tables/appendix tables appear to correspond to objects present in the source (`tab:placebo`, `tab:polykernel`, `tab:dow`, etc.). Figures are referenced and included via filenames (cannot verify file existence from LaTeX alone, but there’s no internal “missing figure/table” reference in the source).

No fatal completeness failures found.

## 4) Internal Consistency (CRITICAL)

- Timing/sample-period statements are broadly consistent: submissions 2012–2024; citation measurement as of early 2026; 18-month outcomes restricted accordingly.
- Cutoff direction is consistent: “After cutoff” corresponds to being listed near the top of the next batch; “before” near bottom of current batch.
- One minor *potential* inconsistency in wording (not fatal): Table `tab:citations` notes “1-year citations use papers submitted through early 2025,” but the paper elsewhere states the submission sample is 2012–2024, so that restriction is automatically satisfied and could be rephrased. This does **not** make the design impossible or the tables incoherent.

No fatal internal inconsistency found.

ADVISOR VERDICT: PASS